

APOTEX INC., APOTEX CORP.,
ARGENTUM PHARMACEUTICALS LLC,
ACTAVIS ELIZABETH LLC, TEVA PHARMACEUTICALS USA, INC.,
SUN PHARMACEUTICAL INDUSTRIES, LTD.,
SUN PHARMACEUTICAL INDUSTRIES, INC., and
SUN PHARMA GLOBAL FZE,
Petitioners,

v.

NOVARTIS AG.,
Patent Owner.

Case IPR2017-00854¹
Patent US 9,187,405 B2

Before LORA M. GREEN, CHRISTOPHER M. KAISER,
and ROBERT A. POLLOCK, *Administrative Patent Judges*.

POLLOCK, *Administrative Patent Judge*.

ORDER
Conduct of the Proceeding
Revising Due Dates 1–7
37 C.F.R. § 42.5

¹Cases IPR2017-01550, IPR2017-01946, and IPR2017-01929 have been joined with this proceeding.

IPR2017-00854
Patent 9,187,405 B2

In response to the October 5, 2017, correspondence from parties relating to Patent Owner's desire to seek an extension of the schedule for IPR2017-00854 and consolidated cases in light of the Federal Circuit's decision in *Aqua Products, Inc. v. Matal*, No. 2015-1177 (Fed. Cir. Oct. 4, 2017), we indicated that we would postpone Due Date 1 by four weeks to Friday, November 10, 2017, and adjust the remaining Due Dates accordingly to avoid inconveniencing either party. *See* Ex. 3003.

Accordingly, it is

ORDERED that Due Dates 1–7 are revised as follows:

| | |
|---|-------------------|
| DUE DATE 1 | November 13, 2017 |
| Patent owner's response to the petition | |
| Patent owner's motion to amend the patent | |
| DUE DATE 2 | February 2, 2018 |
| Petitioner's reply to patent owner's response to petition | |
| Petitioner's opposition to motion to amend | |
| DUE DATE 3 | March 2, 2018 |
| Patent owner's reply to petitioner's opposition to motion to amend | |
| DUE DATE 4 | March 23, 2018 |
| Motion for observation regarding cross-examination of reply witness | |
| Motion to exclude evidence | |
| Request for oral argument | |

IPR2017-00854
Patent 9,187,405 B2

DUE DATE 5 April 6, 2018

Response to observation

Opposition to motion to exclude

DUE DATE 6 April 13, 2018

Reply to opposition to motion to exclude

DUE DATE 7 May 11, 2018

Oral argument (if requested)

IPR2017-00854
Patent 9,187,405 B2

FOR PETITIONER SUN PHARMA:

Samuel Park
WINSTON & STRAWN LLP
spark@winston.com

FOR PETITIONER APOTEX:

Steven W. Parmelee
Michael T. Rosato
Jad A. Mills
WILSON SONSINI GOODRICH & ROSATI
sparmelee@wsgr.com
mrosato@wsgr.com jmills@wsgr.com

FOR PETITIONER ARGENTUM:

Teresa Stanek Rea
Deborah H. Yellin
Shannon M. Lentz
CROWELL & MORING LLP
TRea@Crowell.com
DYellin@crowell.com
SLentz@Crowell.com

Tyler C. Liu
ARGENTUM PHARMACEUTICALS, LLC
TLiu@agpharm.com

FOR PETITIONER TEVA:

Amanda Hollis
Eugene Goryunov
KIRKLAND & ELLIS LLP
amanda.hollis@kirkland.com
egoryunov@kirkland.com

FOR PATENT OWNER:

Jane M. Love
GIBSON, DUNN & CRUTCHER LLP
jlove@gibsondunn.com